Outcomes after intensive ADT and surgery in high-risk men with localized disease

The initial results of a small Phase II trial of androgen deprivation therapy (ADT) + abiraterone acetate prior to surgery in high-risk patients have now been published. … READ MORE …

Use of bisphosphonate therapy in men on ADT in Ontario, Canada

According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …

Survival of prostate cancer patients diagnosed with M1 disease in the modern era

Back in the late 1980s and early 1990s, the projected survival time for a man diagnosed with evident metastatic prostate cancer (then called D2 disease and now known as TxNxM1 disease) was about 18 to 36 months. Has that really changed in the past 25 years? … READ MORE …

Heart-related mortality in men on ADT: a current perspective

A newly published study in BJU International suggests (unsurprisingly) that androgen deprivation therapy (ADT) is associated with an increased risk of death among men with such cardiovascular conditions as congestive heart failure or prior heart attacks. … READ MORE …

“Sexual bother” in advanced prostate cancer patients on androgen deprivation therapy

“Sexual bother” is a term used in the urology literature to refer to the side effects of all sorts of different treatments as they relate to everything from sexual desire to actual erectile and sexual function, the ability to ejaculate, etc. Frankly, it is not a term we like a lot because it encompasses such a vast range of sexually problematic issues. … READ MORE …

Results of the RADAR trial at 7.4 years of follow-up

The RADAR trial (also known as TROG 03.04) was a randomized trial of 6 months of androgen deprivation therapy (ADT) + radiation therapy versus 18 months of ADT + radiotherapy, with or without additional zoledronic acid therapy, in men with intermediate- and high-risk, locally advanced prostate cancer. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,185 other followers